QRxPharma Successfully Completes Comparative Study For Dual-Opioid(TM) Pain Therapy

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced the successful completion of a Phase 3 program pilot study comparing the efficacy and safety profile of MoxDuo(TM) IR against component doses of morphine and oxycodone. Results demonstrated that MoxDuo(TM) IR reduces pain significantly more than its component doses; further, when compared to equianalgesic doses of morphine and oxycodone, MoxDuo(TM) IR produced fewer and less intense side effects.

More: continued here

Filed under: Pain / Anesthetics on April 26th, 2009